ArriVent Doses First Patient in Phase 1 Trial of Dual-Target ADC ARR-002
AVBP sits 45% above its 52-week low of $11.36.
Summary
ArriVent has dosed the first patient with ARR-002, its novel tetravalent MUC16/NaPi2b dual-target antibody-drug conjugate. This marks the start of clinical development for a second pipeline asset, coming just days after the Phase 3 failure of lead drug firmonertinib in first-line EGFR exon 20 NSCLC. The company is pivoting attention to earlier-stage programs as its lead candidate's path forward narrows. ARR-002 targets two tumor antigens simultaneously, a differentiated approach in the ADC space. No efficacy or safety data are available yet; this is an early-stage milestone. The news follows OrbiMed's recent stake reduction to 5.8% after the firmonertinib setback.
At the time of this announcement, AVBP was trading at $16.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $811.6M. The 52-week trading range was $11.36 to $35.83. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.